Literature DB >> 20082184

Radiation therapy for early stages of morbus Ledderhose.

Reinhard Heyd1,2, Anne Pia Dorn3, Markus Herkströter4, Claus Rödel5, Marcus Müller-Schimpfle3, Ingeborg Fraunholz5.   

Abstract

PURPOSE: To evaluate the efficacy of radiation therapy (RT) in the treatment of early stages of benign plantar fibromatosis (Morbus Ledderhose [ML]). PATIENTS AND METHODS: From 2003 to 2008, 24 patients (33 sites) with a mean age of 52 years received RT for symptomatic ML. Prior to RT, 19 patients complained of pain and 15 had walking difficulties. 21 patients (28 sites) were irradiated with orthovoltage X-rays and three (five sites) received electron-beam irradiation. The RT protocol consisted of five weekly fractions of 3.0 Gy (15 Gy), repeated after 6 weeks to a total dose of 30 Gy in 20 patients (28 sites). In four patients (five sites), two single fractions of 4.0 Gy were applied, repeated at intervals of 4 weeks to total doses of 24-32 Gy. Primary study endpoints were the prevention of disease progression and the avoidance of a surgical intervention. Secondary endpoints were pain relief, improvement of gait, and patients' subjective satisfaction measured with a linear analog scale (LAS).
RESULTS: After a median follow-up of 22.5 months, none of the patients experienced a progression of number and size of the lesions or the clinical symptoms. In eleven sites (33.3%) complete remission of cords or nodules occurred, in 18 (54.5%) a reduced number or size was noted, and four sites (12.1%) were unchanged. Pain relief was achieved in 13/19 patients (68.4%), and an improvement of gait abnormalities was noted in 11/15 patients (73.3%). The patients' subjective satisfaction measured by means of the LAS revealed a median improvement of 3.5 points in 22/24 patients (91.6%). Skin or soft tissues toxicities RTOG grade > 2 were not noted.
CONCLUSION: RT is effective for treatment of the early stages of ML and may obviate the need for a surgical intervention. Long-term follow-up studies including a larger number of patients are required to define the role of RT in the management of this disorder.

Entities:  

Mesh:

Year:  2009        PMID: 20082184     DOI: 10.1007/s00066-009-2049-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  31 in total

1.  Soft-tissue tumors of the sole; with special reference to plantar fibromatosis.

Authors:  R A ALLEN; L B WOOLNER; R K GHORMLEY
Journal:  J Bone Joint Surg Am       Date:  1955-01       Impact factor: 5.284

2.  ["Ledderhose" disease. Plantar fibromatosis--clinical aspects].

Authors:  B Parnitzke; O Decker; U Neumann
Journal:  Zentralbl Chir       Date:  1991       Impact factor: 0.942

3.  [Optimization of radiotherapy in Dupuytren's disease. Initial results of a controlled trial].

Authors:  M H Seegenschmiedt; T Olschewski; F Guntrum
Journal:  Strahlenther Onkol       Date:  2001-02       Impact factor: 3.621

4.  Plantar fibromatosis.

Authors:  E Aviles; M Arlen; T Miller
Journal:  Surgery       Date:  1971-01       Impact factor: 3.982

Review 5.  Recurrent plantar fibromatosis.

Authors:  P A Landers; G V Yu; J M White; A K Farrer
Journal:  J Foot Ankle Surg       Date:  1993 Jan-Feb       Impact factor: 1.286

6.  Dupuytren's disease of the plantar fascia.

Authors:  D J Cavolo; G F Sherwood
Journal:  J Foot Surg       Date:  1982

Review 7.  Plantar fibromatosis of the heel in children: a report of 14 cases.

Authors:  G A Godette; M O'Sullivan; M B Menelaus
Journal:  J Pediatr Orthop       Date:  1997 Jan-Feb       Impact factor: 2.324

8.  [Dupuytren's contracture. Radiotherapy in the early stages].

Authors:  M Herbst; G Regler
Journal:  Strahlentherapie       Date:  1985-03

9.  [Plantar fibromatosis: therapy by total plantarfasciectomy].

Authors:  J Beckmann; T Kalteis; W Baer; J Grifka; K Lerch
Journal:  Zentralbl Chir       Date:  2004-01       Impact factor: 0.942

10.  Plantar fibromatosis: a review of primary and recurrent surgical treatment.

Authors:  K L Wapner; P A Ververeli; J H Moore; P J Hecht; C E Becker; R D Lackman
Journal:  Foot Ankle Int       Date:  1995-09       Impact factor: 2.827

View more
  12 in total

1.  T2 signal intensity as an imaging biomarker for patients with superficial Fibromatoses of the hands (Dupuytren's disease) and feet (Ledderhose disease) undergoing definitive electron beam irradiation.

Authors:  James S Banks; Aaron H Wolfson; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2017-10-30       Impact factor: 2.199

2.  DEGRO guidelines for the radiotherapy of non-malignant disorders : part III: hyperproliferative disorders.

Authors:  M Heinrich Seegenschmiedt; Oliver Micke; Marcus Niewald; Ralph Mücke; Hans Theodor Eich; Jan Kriz; Reinhard Heyd
Journal:  Strahlenther Onkol       Date:  2015-03-10       Impact factor: 3.621

Review 3.  Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved.

Authors:  M Arenas; S Sabater; V Hernández; A Rovirosa; P C Lara; A Biete; J Panés
Journal:  Strahlenther Onkol       Date:  2012-08-22       Impact factor: 3.621

4.  Reirradiation of spinal column metastases: comparison of several treatment techniques and dosimetric validation for the use of VMAT.

Authors:  Florian Stieler; Dirk Wolff; Linda Bauer; Hans-Jörg Wertz; Frederik Wenz; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2011-06-27       Impact factor: 3.621

5.  Gorham-Stout syndrome of the pelvic girdle treated by radiation therapy: a case report.

Authors:  Reinhard Heyd; Daniela Rabeneck; Oliver Dörnenburg; Nikolaos Tselis; Nikolaos Zamboglou
Journal:  Strahlenther Onkol       Date:  2011-01-18       Impact factor: 3.621

6.  [The significance of radiation therapy for symptomatic vertebral hemangiomas (SVH)].

Authors:  Reinhard Heyd; M Heinrich Seegenschmiedt; Dirk Rades; Cornelia Winkler; Hans T Eich; Frank Bruns; Georg Gosheger; Normann Willich; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2010-07-29       Impact factor: 3.621

7.  Radiotherapy for calcaneodynia. Results of a single center prospective randomized dose optimization trial.

Authors:  O J Ott; C Jeremias; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2013-02-28       Impact factor: 3.621

8.  Radiotherapy for achillodynia : results of a single-center prospective randomized dose-optimization trial.

Authors:  O J Ott; C Jeremias; U S Gaipl; B Frey; M Schmidt; R Fietkau
Journal:  Strahlenther Onkol       Date:  2012-12-21       Impact factor: 3.621

Review 9.  Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.

Authors:  M H Seegenschmiedt; O Micke; R Muecke
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

10.  Dupuytren-Like Contracture of the Foot: Ledderhose Disease.

Authors:  Osman Akdag; Gokce Yildiran; Mehtap Karamese; Zekeriya Tosun
Journal:  Surg J (N Y)       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.